Rashmi Virendra Ramchandani
Known title: VP, Chief Accounting OfficerCIK: 0002106034
Associated companies
Transaction History
| BMRN | ▲ Buy | Grant | 18,540 | $0 | 1/20/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 7,070 | $0 | 1/20/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 18,540 | $0 | 1/20/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 7,070 | $0 | 1/20/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.